

## What's the Consensus on Cardiorenal Protection for CKD in T2D?

### **Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)**

de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*. 2022;45(12):3075-3090. doi:10.2337/dci22-0027

Link: <https://diabetesjournals.org/care/article-pdf/45/12/3075/716256/dci220027.pdf>

### **The evolution of “pillars of therapy” to reduce heart failure risk and slow diabetic kidney disease progression.**

Blazek O, Bakris GL. The evolution of “pillars of therapy” to reduce heart failure risk and slow diabetic kidney disease progression. *Am Heart J Plus*. 2022;19:100187. doi:10.1016/j.ahjo.2022.100187

Link:

<https://www.sciencedirect.com/science/article/pii/S2666602222001045/pdf?md5=8bc183a540ebeb635f72415a5a4b8149&pid=1-s2.0-S2666602222001045-main.pdf>

### **Albuminuria and heart failure: JACC state-of-the-art review**

Khan MS, Shahid I, Anker SD, et al. Albuminuria and heart failure: JACC state-of-the-art review. *J Am Coll Cardiol*. 2023;81(3):270-282. doi:10.1016/j.jacc.2022.10.028

Link: <https://www.jacc.org/doi/abs/10.1016/j.jacc.2022.10.028>

### **KDIGO. 10 key takeaways for clinicians from the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD.**

Link: <https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Diabetes-Management-in-CKD-Guideline-Top-10-Takeaways-for-Clinicians.pdf>

### **KIDNEY NUMBERS and the CKD HEAT MAP - Educate Your Patients**

Link: [https://www.kidney.org/sites/default/files/heat\\_map\\_card.pdf](https://www.kidney.org/sites/default/files/heat_map_card.pdf)

## **Finerenone Clinical Trials**

### **FIDELIO**

#### **Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes**

Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845

Link: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2025845?articleTools=true>

### **FIGARO**

#### **Cardiovascular events with finerenone in kidney disease and type 2 diabetes**

Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med*. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956

Link: <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110956?articleTools=true>

### **FIDELITY**

#### **Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis**

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [published correction appears in *Eur Heart J*. 2022;43(20):1989]. *Eur Heart J*. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777

Link: <https://academic.oup.com/eurheartj/article-pdf/43/6/474/46630042/ehab777.pdf>